GENELUX Corp GNLX
A.
is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients
suffering from aggressive and/or difficult-to-treat tumor types. Our clinical and preclinical product candidates are intended to selectively
kill tumor cells and induce a robust immune response against a patient's tumor neoantigens. Importantly, our oncolytic immunotherapy
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8.0K | $8.0K | $170.0K | $11.1M | — |
| R&D | $19.9M | $19.0M | $12.8M | $9.1M | — |
| SG&A | $13.4M | $12.7M | $11.6M | $5.0M | — |
| Total operating expenses | $33.2M | $31.7M | $24.3M | $14.1M | — |
| Operating income | -$33.2M | -$31.7M | -$24.2M | -$3.0M | — |
| Interest expense | — | — | $173.0K | — | — |
| Pre-tax income | — | — | — | -$4.1M | — |
| Income tax | — | — | — | $1.1M | — |
| Net income | -$32.1M | -$29.9M | -$28.3M | -$5.2M | — |
| EPS, basic | -0.86 | -0.95 | -1.16 | -0.57 | — |
| EPS, diluted | -0.86 | -0.95 | -1.16 | -0.57 | — |
| Shares, diluted (wtd. avg.) | 37.2M | 31.5M | 31.5M | 9.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $5.3M | $8.6M | $9.4M | $397.0K | $4.5M |
| Short-term investments | — | $22.3M | $13.8M | — | — |
| Total current assets | $15.1M | $31.5M | $24.2M | $1.9M | — |
| Property, plant and equipment | $2.2M | $1.3M | $1.2M | $644.0K | — |
| Total assets | $19.0M | $34.7M | $27.9M | $5.5M | — |
| Accounts payable | $4.4M | $5.6M | $3.8M | $6.8M | — |
| Short-term debt | — | — | $900.0K | — | — |
| Total current liabilities | $6.2M | $6.9M | $6.6M | $31.6M | — |
| Total liabilities | $7.5M | $8.4M | $8.4M | $41.3M | — |
| Retained earnings | -$283.5M | -$251.4M | -$221.5M | -$189.8M | — |
| Total equity | $11.5M | $26.3M | $19.5M | -$35.8M | -$33.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.3M | -$21.2M | -$20.3M | -$3.6M | — |
| Depreciation and amortisation | $244.0K | $235.0K | $499.0K | $553.0K | — |
| Stock-based compensation | $5.9M | $5.7M | $2.5M | $2.4M | — |
| Capital expenditure | $1.1M | $381.0K | $1.0M | $49.0K | — |
| Investing cash flow | $12.1M | -$8.1M | -$14.7M | -$49.0K | — |
| Financing cash flow | $9.9M | $28.5M | $44.0M | -$478.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-011616.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $11.1M | $170.0K | $8.0K | $8.0K |
| Gross profit | — | — | — | — | — |
| Net income | — | -$5.2M | -$28.3M | -$29.9M | -$32.1M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Annual report filed Form 10-K
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |